What is the ticker symbol for Freeline Therapeutics?

Freeline Therapeutics trades under the ticker FRLN on NASDAQ.

What sector does Freeline Therapeutics operate in?

Freeline Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze FRLN in a portfolio?

PortView shows FRLN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Freeline Therapeutics (FRLN) Stock Analysis

NASDAQHealthcareBiotechnology

$6.49+0.15%

1-year price historyRange $2.22 – $7.73

52-week range$6.49

$2.11$8.75

Track FRLN in your portfolio for free · Portfolio tracker

What Freeline Therapeutics does

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Key metrics

Market cap

$28.28M

P/E (TTM)

-0.57

EPS (TTM)

$-11.40

Beta

0.66

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$6.40

200-day avg

$4.57

52-week high

$8.75

52-week low

$2.11

CEO

Michael J. Parini

ETFs linked to FRLN

Broad-market and Healthcare sector ETFs an investor holding Freeline Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how FRLN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze FRLN in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Freeline Therapeutics?: Freeline Therapeutics trades under the ticker FRLN on NASDAQ.
Which exchange is FRLN listed on?: FRLN is listed on NASDAQ.
What sector does Freeline Therapeutics operate in?: Freeline Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze FRLN in a portfolio?: PortView shows FRLN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.